DAPT (GSI-IX) is a novel γ-secretase (γ-secretase) inhibitor that inhibits the production of total Aβ and Aβ42 in cells, which in turn affects cell signaling and cell differentiation. DAPT reduces the total Aβ yield in HEK 293 cells, with an IC50 of 20 nM in HEK 293 cells. DAPT inhibits the production of Aβ and Aβ42 in human neurocytes respectively with IC50 of 115 nM and 200 nM, which are 5-10-fold lower than those when applied to HEK 293 cells. DAPT inhibits SK-MES-1 cell proliferation in a concentration-dependent manner with an IC50 of 11.265 μM. In addition, DAPT acts on lung squamous cell carcinoma cells and induces apoptosis-dependent and non-dependent apoptosis by inhibiting the Notch receptor signaling pathway. DAPT reduces lymphoid tissue proliferation in CBA-lprg mice and autoimmunity in MRL-lprr mice, and also exhibits resistance for several months in vivo, so DAPT has the potential to be an effective candidate in clinical trials for ALPS and lupus erythematosus (SLE). Features Purity≥98% Standardized production, using factory mass production mode Specifications Cat.No. 52104ES10/52104ES50 Size 10 mg/50 mg Synonym DAPT; LY374973; GSIIX CAS No. 208255-80-5 Molecular formula C23H26F2N2O4 Molecular weight 432.46 Appearance solid powder Purity ≥98% Solubility Soluble in DMSO (20 mg/mL) Structure Components Components No. Name 52104ES10 52104ES50 52104 DAPT 10 mg 50 mg Shipping and Storage The DAPT products should be stored at -15～-25℃ for 2 years. Avoid repeated freeze-thaw cycles. Documents: Safety Data Sheet 52104_MSDS_HB20250210 _EN.pdf Manuals 52104_Manual_HB20250210 _EN.pdf
